2022 GBT440-042 – Phase 3, Multicenter, Randomized, Double-Blind, PlaceboControlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.
Previous Post2021 GBT440-032 “HOPE Kids 2” – A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Paediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease
Next Post2021 GBT2104-131 – A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises
